Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 331

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Open access
Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Pollyea, Daniel A., Stone, Richard M., Altman, Jessica K., Roboz, Gail J., Patel, Manish R., Collins, Robert, Flinn, Ian W., Sekeres, Mikkael A., Stein, Anthony S., Kantarjian, Hagop M., Levine, Ross L., Vyas, Paresh, MacBeth, Kyle J., Tosolini, Alessandra, VanOostendorp, Jason, Xu, Qiang, Gupta, Ira, Lila, Thomas, Risueno, Alberto, Yen, Katharine E., Wu, Bin, Attar, Eyal C., Tallman, Martin S., de Botton, Stéphane·2019·Blood

Abstract

Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62%) with relapsed or refractory (R/R) AML received enasidenib, 100 mg/d. Median age was 68 years. Forty-two patients (19.6%) attained complete remission (CR), 19 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall response rate was 38.8% (95% confidence interval [CI], 32.2-45.7). Median overall survival was 8.8 months (95% CI, 7.7-9.6). Response and survival were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Response rates were similar among patients who, at study entry, were in relapse (37.7%) or were refractory to intensive (37.5%) or nonintensive (43.2%) therapies. Sixty-six (43.1%) red blood cell transfusion–dependent and 53 (40.2%) platelet transfusion–dependent patients achieved transfusion independence. The magnitude of 2-HG reduction on study was associated with CR in IDH2-R172 patients. Clearance of mutant-IDH2 clones was also associated with achievement of CR. Among all 345 patients, the most common grade 3 or 4 treatment-related adverse events were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation syndrome (6%). Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered at www.clinicaltrials.gov as #NCT01915498.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2018-08-869008

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 331

Metadata

Authors
Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., Sekeres, M. A., Stein, A. S., Kantarjian, H. M., Levine, R. L., Vyas, P., MacBeth, K. J., Tosolini, A., VanOostendorp, J., Xu, Q., Gupta, I., Lila, T., Risueno, A., Yen, K. E., Wu, B., Attar, E. C., Tallman, M. S., & de Botton, S.
Venue
Blood
Published
2019-02-14
Volume
133
Issue
7
Pages
676-687
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2902301444
Cited by
331
References
32
FWCI
28.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. https://app.cochat.ai/papers/10.1182/blood-2018-08-869008
The paper
Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., Sekeres, M. A., Stein, A. S., Kantarjian, H. M., Levine, R. L., Vyas, P., MacBeth, K. J., Tosolini, A., VanOostendorp, J., Xu, Q., . . . de Botton, S. (2019). Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. https://doi.org/10.1182/blood-2018-08-869008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.